FORM 6-K

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934


For period ending May 29, 2008

GlaxoSmithKline plc
(Name of registrant)

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


Form 20-F x Form 40-F
 --


Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No x
  --

 

 
   
    
    
    
    
    
       
 
   
   
  FORM 8.3
    
    
    
    
    
    
DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE 
(Rule 8.3 of 
t
he 
Takeover 
Code)


1.
    KEY INFORMATION

Name of person dealing 
 
(Note 1)
 
GlaxoSmithKline plc and its subsidiaries
Company dealt in
CeNeS Pharmaceuticals plc 
Class of relevant security to which the dealings being disclosed relate
 
(Note 2)
Ordinary 30p shares
Date of dealing
2
9
 May 2008




2.
    INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a)
    
Interest
s
 and short positions
 
(following dealing) in the class of relevant security dealt in 
(Note 3)



Long
Short


Number  
   
  (%)
Number  
  
(%)
(1) Relevant securities 

563,5
68
  2.56%  

(2) D
erivatives
 (other than options)



(3) 
Options
 and agreements to purchase/sell



Total

563,568
  2.56%  




(
b
)
    
Interest
s
 and short positions
 
in relevant securities of the company, other than the 
c
lass 
dealt in
 
(Note 3)

Class of relevant security:

Long
Short


Number  
   
  (%)
Number  
   
  (%)
(1) Relevant securities 



(2) D
erivatives
 (other than options)



(3) 
Options
 and agreements to purchase/sell



Total






(c)
    R
ights to subscribe
 
(Note 3)

Class of relevant security
:

Details







3.
    DEALINGS 
(Note 4)

(a)
    
Purchases and sales

Purchase/sale

Number of securities
Price per unit
 
(Note 5)








(b)
    
Derivatives transactions (other than options)

Pr
oduct name
,
 
e.g. CFD
Long/short 
(Note 
6
)
Number of securities
 
(Note 7)
Price per unit 
(Note 5)










(c)
    O
ptions transactions in respect of existing securities
(i)
    
Writing, selling, purchasing or varying

Product name
,
e.g.
 call 
option

Writing, selling, purchasing, varying etc.
Number of securities 
to which the option relates 
(Note 7)
Exercise
price 
Type
,
 e.g. American, European etc.
Expiry 
d
ate
Option money
paid/received 
per unit 
(Note 5)
 











(ii)
    
Exercising

Product name
,
 e.g.
 call option
Number of securities 
Exercise price 
per unit 
(Note 5)








(d)
    
Other dealings (including new securities)
 
(Note 4)

Nature of transaction 
(Note 8)

Details
Price 
per unit
 (if applicable)
 
(Note 5)
Issue of shares

120,752 Ordinary shares
 of 30p each
 issued pursuant to a share exchange agreement dated 
21 November 2003
 between CeNeS 
Pharmaceuticals plc 
and 
GlaxoSmithKline
. 
N
ot Applicable













4.
    O
THER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives


Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or
 relating to the voting rights or
 future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.  







Is a Supplemental Form 8 attached? 
(Note 9)
    
    
    
    
NO


Date of disclosure
2
9
 May 2008
Contact name
Victoria Whyte
Telephone number
020 8047 5000
If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, 
state nature
 of connection 
(Note 
10
)





Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at 
www.thetakeoverpanel.org.uk


 


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 

                                                             GlaxoSmithKline plc
                                                                    (Registrant)

Date: May 29, 2008

                                                                                                        By: VICTORIA WHYTE
                                                                                                                                                                ------------------
                                                              Victoria Whyte
                                                 Authorised Signatory for and on
                                                   behalf of GlaxoSmithKline plc